Sharemaestro Newsreel

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - August 4, 2026

Twist Bioscience Corporation announced that it will grant a total of 44,434 restricted stock units (RSUs) to 24 recently hired individuals as an inducement for their employment. These grants are made under Twist's Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq …

IDEXX (IDXX) Stock Rewards Margin Strength And Recurring Diagnostics Growth

ADAPTIVE BIOTECHNOLOGIES CORP : PIPER SANDLER RAISES TARGET PRICE TO $27.50 FROM $20.00

Piper Sandler has increased its target price for Adaptive Biotechnologies Corp to $27.50 from $20.00. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The information was reported by Reuters.

William Blair Maintains IDEXX Laboratories Inc(IDXX.US) With Buy Rating

William Blair has reiterated its Buy rating on IDEXX Laboratories Inc (IDXX.US). This continued endorsement reflects a positive outlook from the firm regarding the company's performance and prospects.

QIAGEN NV Revenue Breakdown – BIVA:QIA/N

QIAGEN NV (BIVA:QIA/N) generated 37.68 billion MXN in revenue last year. Its top-performing segment was Diagnostic Solutions, contributing 14.48 billion MXN. The United States was the largest regional contributor, accounting for 18.00 billion MXN of the total revenue.

Danaher (NYSE: DHR) director adds phantom share units via fee deferral

Danaher director Linda Filler acquired 18.333 phantom shares on July 31, 2026, through the company's Non-Employee Directors Deferred Compensation Plan. These phantom shares, valued at $194.98 each, are fully vested and will convert into common stock on a one-for-one basis upon distribution. Following this …

(PRPO) Movement as an Input in Quant Signal Sets

This article analyzes Precipio Inc. (NASDAQ: PRPO) using AI models to generate trading strategies across different risk profiles. Key findings indicate divergent sentiment, suggesting choppy conditions, and highlights support and resistance levels. The analysis provides specific entry, target, and stop-loss zones for position trading, …

Why Waters Corporation (WAT) Stock Is Trading Up Today

Adaptive Biotechnologies (NASDAQ: ADPT) raises $345M in 2031 notes

Adaptive Biotechnologies (ADPT) has issued $345 million in 0% convertible senior notes due 2031, using part of the proceeds to repurchase revenue interests and common stock. The company reported a Q2 2026 revenue of $71.6 million, an increase from the previous year, driven by …

BRIEF-Exagen Inc. Q2 Revenue USD 19.941 Million Vs. IBES Estimate USD 17.8 Million

Exagen Inc. reported its Q2 revenue at $19.941 million, surpassing the IBES estimate of $17.8 million. The brief financial update indicates a stronger-than-expected performance for the company in the second quarter.

Mettler-Toledo International Inc. Just Recorded A 9.8% EPS Beat: Here's What Analysts Are Forecasting Next

Mettler-Toledo International Inc. recently reported a 9.8% EPS beat, surpassing analyst expectations. This article will likely discuss the company's latest financial results and provide insights into what analysts are predicting for Mettler-Toledo's future performance based on these strong earnings. It will likely cover key …

Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market

Shares of Thermo Fisher Scientific Inc. fell 1.62% to $564.75 on Tuesday, marking its third consecutive day of losses. This occurred despite a strong overall market performance, with the S&P 500 Index rising 1.79% and the Dow Jones Industrial Average rising 1.71%. The stock …

IQVIA Holdings Officer Sold Shares Worth Over $1.2M

Staub W Richard, an Officer at IQVIA Holdings and President, Research & Development Solutions, sold common stock worth $1,279,740 on August 3, 2026, at $232.68 per share. Following this transaction, Staub directly owns 13,312 shares. The sale was reported via an SEC Form 4 …

Danaher (DHR) Names Its Next CEO, Is The Stock Still Undervalued?

VERACYTE INC : PIPER SANDLER CUTS TARGET PRICE TO $54.00 FROM $66.00

Piper Sandler has reduced its target price for VERACYTE INC (VCYT.O) to $54.00 from $66.00. This report was issued by Reuters on August 4, 2026. The article advises readers that its content reflects the author's opinion and should not be used as the sole …

IQVIA HOLDINGS INC. (IQV) officer sells 5,500 shares at $232.68

W. Richard Staub, an officer at IQVIA HOLDINGS INC. (IQV), sold 5,500 shares of common stock on August 3, 2026, at a price of $232.68 per share, totaling $1.28 million. Following the transaction, Staub directly owns 13,312 shares, and the sale was not conducted …

Personalis (NASDAQ:PSNL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Worker alleges lack of fossil fuel-free 401(k) option violated his religious rights

A statistical science director at Thermo Fisher Scientific has filed a lawsuit alleging that the company violated his religious rights by not providing a fossil fuel-free 401(k) investment option. The worker, a committed Christian, believes his faith calls him to protect the Earth and …

Bruce Bernstein details 6.9% XWELL, Inc. (XWEL) stake, sale support

Bruce Bernstein, Chairman of XWELL, Inc., reported a 6.9% beneficial ownership stake in the company, totaling 602,556 shares. He has committed to voting his shares in favor of the sale of XWELL's equity interests in XpresSpa Holdings, LLC and XpresTest, Inc. to Express Wellness …

Bruce Bernstein Backs Asset Sale at XWELL with 6.9% Stake

Bruce Bernstein, Chairman of XWELL, Inc., has disclosed a 6.9% beneficial stake in the company and officially committed to supporting the planned sale of its XpresSpa and XpresTest subsidiaries. He has entered a Support Agreement, pledging to vote in favor of the asset sale …

Guardant Health (GH) insider Ian T. Clark plans potential sale of 14,180 shares

Guardant Health (GH) insider Ian T. Clark has filed a Form 144 notice for a proposed sale of 14,180 shares of common stock, valued at approximately $2,253,450.00. The sale is planned for around August 4, 2026, through Charles Schwab & Co., Inc. on NASDAQ. …

Natera (NTRA) insider Michael Brophy plans 478-share stock sale after RSU award

Natera insider Michael Brophy has filed a Form 144 notice to sell 478 shares of common stock, valued at $129,232.08, through Morgan Stanley Smith Barney LLC on or about August 4, 2026. These shares were acquired from Restricted Stock Units on July 31, 2026. …

No-Moat Revvity Sees Solid First-Half Performance With Momentum Likely to Continue

Revvity, formerly PerkinElmer, has demonstrated solid first-half performance in 2026, with strong earnings boosting its outlook. The company, which rebranded after divesting its applied, food, and enterprise services business, now focuses on diagnostics and life sciences. This positive momentum is expected to continue, driven …

Danaher (NYSE: DHR) director defers fees into 236.633 phantom shares

Danaher Corporation director Elias A. Zerhouni acquired 236.633 phantom shares on July 31, 2026, as part of the Non-Employee Directors Deferred Compensation Plan. These shares were calculated using Danaher's NYSE closing price of $194.98 and are fully vested, convertible one-for-one into common stock upon …

BillionToOne (BLLN) CPO sells 4,000 shares under Rule 10b5-1 plan

BillionToOne, Inc.'s Chief Product Officer, Sakakibara Shan Riku, sold 4,000 shares of Class A Common Stock on July 31, 2026, at $140.21 per share. This transaction, valued at $561,000, was executed under a pre-established Rule 10b5-1 trading plan adopted on March 6, 2026. Following …

Adaptive Biotechnologies Corp Q2 2026: Revenue $71.6M, EPS $(0.25) — 10-Q Summary

Adaptive Biotechnologies Corp (ADPT) reported Q2 2026 financial results, with revenue reaching $71.6 million, an increase from $58.9 million in the previous year. The company recorded a net loss of $(39.8) million and a diluted loss per share of $(0.25). Key drivers included a …

Earnings Flash (PSNL) Personalis, Inc. Reports Q2 Revenue $22.4M, vs. FactSet Est of $16.7M

Personalis, Inc. (PSNL) announced its Q2 revenue of $22.4 million, significantly exceeding FactSet's estimated $16.7 million. The company, which specializes in advanced cancer genomic tests and analytics, focuses on supporting personalized cancer vaccines and immunotherapies. This earnings beat follows recent news including Tempus AI's …

Personalis (NASDAQ: PSNL) Q2 revenue jumps 30% as clinical tests surge

Personalis, Inc. reported a 30% increase in Q2 2026 revenue to $22.4 million, driven by a 199% surge in clinical test volume and strong pharma testing services. Despite the revenue growth, the company posted a net loss of $31.7 million. Following a merger agreement …

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy's Laboratories has launched Sugammadex Injection 200 mg/2 mL and 500 mg/5 mL Single-Dose Vials in the U.S., a generic equivalent of Bridion®. This first-to-market launch expands their hospital portfolio and aims to provide affordable, high-quality medicine. The product is indicated for reversing …

Release according to Article 40, Section 1 of the WpHG

QIAGEN N.V. has released a notification regarding voting rights, as informed by the AFM. T. Rowe Price Group, Inc. reported a transaction on July 29, 2026, showing a capital interest and voting rights distribution of 4.97% in QIAGEN N.V. The company emphasizes it is …

Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock

Twist Bioscience Corporation announced a proposed underwritten public offering of $250.0 million of its common stock, with an option for underwriters to purchase an additional $37.5 million. The company plans to use the net proceeds, along with existing cash, for research and development investments, …

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

Medical equipment maker Revvity has increased its annual profit and revenue forecasts after exceeding Wall Street expectations for the second quarter. This improvement is attributed to stronger demand for its drug-development tools and diagnostic testing products, with AI-related work contributing to incremental demand. Despite …

RVTY Q2 Earnings Beat Estimates on Diagnostics Strength, '26 View Up

Revvity, Inc. (RVTY) reported strong second-quarter 2026 results, with adjusted EPS of $1.41 and revenues of $729.7 million, both surpassing analyst estimates, driven by strength in its Diagnostics segment. The company also raised its full-year 2026 pro forma outlook for revenues and adjusted EPS. …

Exagen Q2 Earnings Call Highlights

Exagen Inc (XGN) reported record quarterly revenue of $19.9 million in Q2 2026, marking a 16% year-over-year increase, driven by record AVISE test volume and Pharma Services revenue. The company also significantly narrowed its adjusted EBITDA loss to $0.1 million and raised its full-year …

Natera Deadline Alert

Faruqi & Faruqi, LLP is investigating potential claims against Natera, Inc. (NASDAQ: NTRA) and reminds investors of the June 27, 2022 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges Natera made false and misleading statements …

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made …